About Actimed Therapeutics
Focused exclusively on the treatment of muscle wasting disorders, Actimed Therapeutics is advancing a pipeline of novel compounds targeting cancer-related cachexia and related conditions for which no globally approved pharmaceutical treatment currently exists. The clinical-stage biotechnology company aims to transform care for a patient population that has historically been under-served, with a stated goal of prolonging and improving quality of life, restoring dignity, and easing the burden on patients, carers, and healthcare providers alike.
Cancer-related cachexia is a progressive wasting syndrome that accompanies cancer and other serious chronic illnesses. It is associated with significant morbidity and mortality, yet despite its prevalence and devastating clinical impact, therapeutic options remain very limited. Actimed Therapeutics has positioned itself at the frontier of this unmet medical need.
The company's pipeline centres on two investigational agents: S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), both of which are being explored in the context of cachexia, cancer cachexia, muscle optimisation in obesity, and amyotrophic lateral sclerosis. The dual-compound approach reflects a broadening scientific focus on anabolic and anti-catabolic mechanisms in muscle biology.
Governance includes a board, management team, founders, and an advisory panel, indicating an organised leadership structure appropriate to a company at this stage of development. Actimed Therapeutics operates with a clear patient-centred mission, directing its research towards conditions where conventional medicine has yet to deliver a definitive solution.
Further information is available at actimedtherapeutics.com.
